Find the latest pharmaceutical market place for APIs enquiry about Levosimendan on PharmaCompass.com.

Levosimendan (100 g) API needed in Greece [ENA18379]

A company that focuses on research, development & manufacturing of OSDs, injectables and drops is looking for suppliers of Levosimendan (100 g) API for development purposes. The suppliers must support this enquiry with CEP or EUDMF & CoA.

Reply

18 Oct 2023

Uzbekistan Flag

Levosimendan (MOQ) API needed Uzbekistan [ENA07454]

Sorrento Marketing, a marketing company that provides services for the promotion of medicines and medical products is looking for suppliers of Levosimendan (MOQ) API. Interested suppliers can contact them via their email: nsokhibova@sorrento.marketing.

Reply

02 Jun 2020

Russia-big Flag

Levosimendan, Salmeterol Xinafoate and Fluticasone Propionate APIs needed in Russia [ENA03329]

A pharmaceutical trading company in Russia is looking for suppliers of below APIs:
1. Levosimendan - 500 g
2. Salmeterol Xinafoate - 200 g for R&D and 3-5 kg for commercial purposes.
3. Fluticasone Propionate - 400 grams for R&D and 4-6 kg for commercial purposes.

Reply

04 Feb 2019

india-flag Flag

Levosimendan API & Leucovorin Calcium (10 kg each) needed in India [ENA02405]

A leading Indian pharmaceutical formulations manufacturers if looking for suppliers of Levosimendan API & Leucovorin Calcium (10 kg each) for domestic consumption.

Reply

24 Oct 2018

Levosimendan (400g) API needed in Chile [ENA02277]

A multi-latin pharmaceutical company that produces small volume parenteral solutions is looking for suppliers of Levosimendan (400g) API. Interested suppliers must support this enquiry with Certificate of Analysis (COA) and a valid GMP certificate.

Reply

12 Oct 2018

Enquiry // Levosimendan API or key intermediates required by leading Indian generic company [EN00178]

A leading Indian generic company is looking for Levosimendan (brand name: Simdax) or its key intermediates. The product’s innovator Orion obtained approval to market the drug in Sweden in 2000 and since then 60 countries worldwide have approved the drug. It remains non licensed in the US and is used in the management of acutely decompensated congestive heart failure.

Reply

24 Nov 2015